Targeting Gal-1 may provide several advantages as a potential therapeutic option for cancer; vaccination against Gal-1 promotes cytotoxic T-cell infiltration, which reduces melanoma burden, and also induces VEGF-like signals [106]. This evidence concerns the gene VEGFA and cancer.